A Riga-based neurotechnology start-up, Qualia, is tapping artificial intelligence to induce non-invasive brain stimulation that can reshape treatment for neurological and mental health conditions, from stroke to chronic depression, Labs of Latvia, a Latvian start-up ecosystem platform and media outlet focused on innovation, entrepreneurship and technology, said on its website on January 5.

Although still in its early stages, Qualia has already gained international exposure; it was nominated as one of the world’s top 200 startups in the Entrepreneurship World Cup, where around 15 000 companies apply each year.

Latvia was chosen deliberately as a European base. Qualia founder Nerses Khachatrian says Khachatrian says that Latvia’s compact ecosystem allows faster links between start-ups, clinics, universities and investors.

Now, Qualia Therapeutics is developing magnetic brain stimulation technology combined with real-time AI analysis. Rather than relying on drugs or surgery, the system aims to alter neural activity patterns directly.

 “This allows us to interfere with brain neurons and achieve outcomes such as stroke treatment and rehabilitation, reduction of chronic pain or chronic depression,” Khachatrian said.

At the core of the platform is an EEG-based monitoring system that feeds live brain data into an AI engine. The company believes the approach could deliver long-lasting results. 

For stroke patients, Qualia combines brain stimulation with electrical muscle stimulation to enhance neuroplasticity.